D 759
Alternative Names: D-759Latest Information Update: 29 Mar 2024
At a glance
- Originator Chong Kun Dang
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 05 Sep 2023 Chong Kun Dang pharmaceuticals completes a phase I trial in Type 2 diabetes mellitus in South Korea (PO) (NCT05928637)
- 10 Jul 2023 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT05928637)